Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment and outcomes of thromboembolism in paediatric patients with cardiac disease in a cardiac ICU: a single-centre retrospective study.

Cardiology in the young·2026
Same author

Contemporary management of pediatric venous thrombosis: how does it differ from adult care?

Journal of thrombosis and haemostasis : JTH·2026
Same author

Pharmacist antithrombotic interventions in critically ill children: A multicenter prospective study.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Optimal dosing of enoxaparin in children with CHD less than 1 year of age.

Cardiology in the young·2026
Same author

Systematic review on the design and methodology of the pediatric direct oral anticoagulant clinical trials for thrombosis prevention: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Cytomegalovirus Breakthrough in Pediatric Cardiac Transplant Recipients Receiving Weight-Based Dosing Valganciclovir Prophylaxis.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2025
Same journal

Ganciclovir Therapeutic Drug Monitoring in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Commentary on "Examining the Evidence Around Acetaminophen and Autism Risk".

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Sweet or Salty: Comparing Dextrose and Sodium Acetate Umbilical Arterial Catheter Fluids.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

A Case of Prolonged Serotonin Toxicity After Fluoxetine Ingestion in an Adolescent Patient.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Efficacy and Safety of Tranexamic Acid in Pediatric Trauma: A Systematic Review and Meta-Analysis.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same journal

Neonatal Opioid Withdrawal Syndrome: 2 Years Later…Where Are We NOWS?

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

Heparin Resistance - A Reality or Fallacy.

Joshua W Branstetter1, Amy L Kiskaddon2

  • 1Department of Pharmacy (JWB), Children's Healthcare of Atlanta, Atlanta, GA.

The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
|June 10, 2026
PubMed
Summary
This summary is machine-generated.

Heparin resistance lacks clear definitions, complicating treatment for both adults and children. This review explores heparin resistance in pediatric patients and suggests management strategies.

Keywords:
antithrombindirect thrombin inhibitorsheparin resistanceunfractionated heparin

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

Related Experiment Videos

Last Updated: Jun 11, 2026

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

Area of Science:

  • Pediatric pharmacology
  • Critical care medicine
  • Hematology

Background:

  • The term "heparin resistance" is frequently used clinically but lacks specific, standardized criteria.
  • Defining a "maximum" heparin dose is problematic, leading to varied clinical interpretations.
  • The context of heparin use (e.g., cardiac surgery vs. intensive care unit) influences perceptions of dose appropriateness.

Purpose of the Study:

  • To provide insights into heparin resistance in pediatric patients.
  • To discuss potential management strategies for heparin resistance.
  • To address the lack of consensus on heparin resistance definition and monitoring.

Main Methods:

  • Literature review on heparin resistance in pediatric populations.
  • Analysis of current clinical practices and definitions.
  • Exploration of monitoring strategies and their limitations.

Main Results:

  • No consensus exists on a standardized definition or maximum heparin dose.
  • Clinical settings and indications significantly impact the perception of heparin dosing.
  • There is a lack of agreement on optimal heparin monitoring strategies.

Conclusions:

  • Standardized criteria for heparin resistance are needed, particularly in pediatrics.
  • Further research is required to establish clear guidelines for heparin dosing and monitoring.
  • Improved understanding and definitions can enhance the management of heparin therapy in children.